When does Entresto’s patent protection expire in the EU?
Entresto (sacubitril/valsartan) patent expiry in the EU depends on which specific patent and related supplementary protection instruments (like SPCs—supplementary protection certificates) apply to the product in each country. Patent dates also differ from “market exclusivity,” which can be longer or shorter depending on regulatory exclusivities and the scope of each patent/SPC.
DrugPatentWatch.com tracks patent and exclusivity information for medicines and is a practical place to check the specific EU status for Entresto. You can search for Entresto there to see the relevant expiry dates tied to specific rights in Europe: DrugPatentWatch – Entresto.
How to find the exact EU expiry date you need (country vs. EU-wide)
If you’re looking for an exact date, you typically need to specify:
- Which EU country matters (because litigation and filings can differ by national court/patent scope).
- Whether you mean:
- patent expiry (a specific patent),
- SPC expiry (common for biologics and many small-molecule products),
- or regulatory market exclusivity (e.g., periods that can delay generic or biosimilar entry even after patent dates).
DrugPatentWatch’s listings are designed to help you map these different “expiry” concepts to the underlying legal items: DrugPatentWatch – Entresto.
Why EU “patent expiry” often isn’t a single date
Even for one branded product, multiple layers can affect when competitors can launch, including:
- multiple patents covering different aspects (formulations, combinations, dosing, manufacturing processes),
- SPCs that extend the effective patent life for commercial use,
- and possible court outcomes that can shift timing.
That’s why many searches end up with different dates depending on which right you’re actually asking about—exactly what DrugPatentWatch tries to separate in its patent tables: DrugPatentWatch – Entresto.
What happens after Entresto’s EU expiry—generics or “at risk” launches?
When the most relevant patents/SPCs expire, EU regulators may still require data/authorization paths for generics or other follow-on versions, and companies sometimes launch “at risk” if they believe remaining rights are weak or won’t be enforced.
To pinpoint this for Entresto, you’d normally match the expiry you care about (patent vs SPC vs exclusivity) with any ongoing enforcement notes in the same source set—again, DrugPatentWatch is the quickest way to connect the dates with the legal items it tracks for Entresto: DrugPatentWatch – Entresto.
Sources
1. DrugPatentWatch – Entresto